This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pentaglobin
DrugBank Accession Number
DB15865
Background

Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations.1 It is comprised of immunoglobulin G (IgG) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).3

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • IgM-enriched immunoglobulins
  • IVIgGM
External IDs
  • Pentaglobin

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Pentaglobin has potential antibacterial and immunomodulatory properties where, compared to immunoglobulin treatments without IgM, pentaglobin may have an increased ability to eliminate infectious pathogens . The IgM in the preparation plays a role in complement activation and neutralization of bacterial endo- and exotoxins.3 Pentaglobin is used as an adjuvant in treatment of severe bacterial infections while it is also investigated against peritonitis, sepsis, and COVID-19.2

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Pentaglobin.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pentaglobin.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Pentaglobin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentaglobin.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Pentaglobin.
AmivantamabThe risk or severity of adverse effects can be increased when Pentaglobin is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Pentaglobin.
AnsuvimabThe risk or severity of adverse effects can be increased when Pentaglobin is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pentaglobin.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pentaglobin.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Neilson AR, Burchardi H, Schneider H: Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005 Sep;20(3):239-49. doi: 10.1016/j.jcrc.2005.03.003. [Article]
  2. Vaira M, Scuderi S, Costamagna D, Barone R, De Simone M: [Use of pentaglobin in the treatment of sepsis in the patient undergoing intraperitoneal hyperthermic chemotherapy]. Tumori. 2003 Jul-Aug;89(4 Suppl):296-7. [Article]
  3. National Cancer Institute: IgM-enriched Immunoglobulins (CUI CL563000) [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentNeonatal Sepsis / Very Low Birth Weight Baby1
4Unknown StatusTreatmentSepsis of the Newborn1
3Not Yet RecruitingPreventionInflammation / Neonatal Early Onset Sepsis / Newborn, Infant, Disease / Very Low Birthweight Infants1
3RecruitingTreatmentHypoglobulinemia / Sepsis / Septic Shock1
2CompletedTreatmentSeptic Shock / Severe Sepsis1
2RecruitingTreatmentSeptic Shock1
2SuspendedTreatmentPeritonitis / Sepsis1
2, 3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
Not AvailableCompletedNot AvailableRespiratory Distress Syndrome, Adult / Septic Shock1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 21, 2020 13:56 / Updated at September 22, 2020 13:00